Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
13.72
-0.41 (-2.87%)
Mar 31, 2025, 1:13 PM EDT - Market open
Inhibrx Biosciences Revenue
In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%. Inhibrx Biosciences had revenue of $100.00K in the quarter ending December 31, 2024, a decrease of -93.88%.
Revenue (ttm)
$200.00K
Revenue Growth
-88.89%
P/S Ratio
1,022.00
Revenue / Employee
$1,242
Employees
161
Market Cap
198.54M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
Dec 31, 2023 | 1.80M | 485.00K | 36.88% |
Dec 31, 2022 | 1.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINBX News
- 13 days ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - PRNewsWire
- 2 months ago - Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PRNewsWire
- 2 months ago - Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - PRNewsWire
- 4 months ago - Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PRNewsWire
- 5 months ago - Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
- 5 months ago - Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - PRNewsWire
- 7 months ago - Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying - Benzinga
- 8 months ago - Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - PRNewsWire